| Cat. No. |
Product Name |
Information |
| PC-70114 |
MM-401
MLL1/WDR5 inhibitor
|
MM-401 is a potent inhibitor of MLL1/WDR5 protein-protein interaction with IC50 of 0.9 nM. |
| PC-70109 |
GSK-2807
|
GSK-2807 (GSK 2807, GSK2807) is a potent and selective, SAM-competitive inhibitor of SMYD3 with Ki of 14 nM. |
| PC-70108 |
BCI-121
SMYD3 inhibitor
|
BCI-121 (BCI121) is a substrate-competitive SMYD3 inhibitor that significantly inhibits SMYD3-substrate interaction and chromatin recruitment and is effective in reducing proliferation in various cancer cells types. |
| PC-70107 |
EPZ-030456
|
EPZ-030456 (EPZ030456) is a potent, selective SMYD3 inhibitor with biochem IC50 of 4 nM. |
| PC-70104 |
MM-589
MLL1/WDR5 inhibitor
|
MM-589 is a highly potent, cell-permeable inhibitor of WDR5-MLL interaction with IC50 of 0.9 nM, Ki of <1 nM. |
| PC-60300 |
MS-453
SETD8 inhibitor
|
MS-453 (MS453) is a potent, selective and covalent protein lysine methyltransferase SETD8 inhibitor with IC50 of 804 nM. |
| PC-60299 |
CPI-1205
|
Lirametostat (CPI-1205) is a highly potent, selective EZH2 inhibitor with biochemical IC50 of 2 nM, cellular EC50 of 32 nM. |
| PC-60263 |
JQEZ5
EZH2 inhibitor
|
JQEZ5 (JQ5, EZ005) is a novel potent, selective, SAM-competitive EZH2 inhibitor with IC50 of 80 nM (inhibition of enzymatic function of PRC2). |
| PC-60256 |
CM-579
G9a inhibitor
|
CM-579 (CM579) is a novel potent, selective and reversible dual inhibitor of G9a/DNMTs with IC50 of 16 nM and 32 nM for G9a and DNMT1, respectively. |
| PC-60255 |
CM-272
G9a/DNMTs inhibitor
|
CM-272 (CM272) is a novel potent, selective and reversible dual inhibitor of G9a/DNMTs with IC50 of 8 nM and 382 nM for G9a and DNMT1, respectively. |
| PC-70002 |
MIV-6R
menin-MLL inhibitor
|
MIV-6R is a potent, ligand-efficient, and cell-active inhibitor menin-MLL interaction with IC50 of 56 nM, Kd of 85 nM. |
| PC-60001 |
PF-06821497 S enantiomer
|
PF-06821497 S enantiomer is a novel potent, selective, orally bioavailable EZH2 inhibitor with Ki of <0.1 and 1.15 nM aginast both wt and mutant Y641N EZH2, respectively. |
